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asymptomatic pediatric IDDM patients. Compared to
other guidelines, this one required prompt initiation,
more frequent eye exams, and earlier ophthalmologist re-
ferrals. OBJECTIVES: The purpose of this study was to
examine the cost-effectiveness of retinopathy screening in
pediatric patients with Type I diabetes under the new
policy. METHODS: Cost-effectiveness model was devel-
oped using Microsoft Excel 7.0, incorporating data from
previous epidemiological studies and clinical trials. Markov
Model was used, combined with sensitivity analysis. RE-
SULTS: Screening in pediatric patients was not only cost-
effective, but was actually cost saving from the societal
perspective. During the first 10 years of IDDM, retinopa-
thy screening was very cost-effective (CER  74$/QALY
at year 5). Starting from the 10th year, the intervention re-
sulted in an increasing level of cost and QALY savings.
The amount of QALY saved and cost savings both peaked
at 15 to 20 years after IDDM onset. Under 100% com-
pliance rate, screening produce average savings of $48,412
and Quality Adjusted Life Year (QALY) saved of 7.15
per patient. Our model was sensitive to the compliance
rate of screening; at 50% compliance rate, the total costs
for detection and treatment increased near 2-fold. Screen-
ing by ophthalmologists instead of primary care physi-
cians reduced the total costs by 53.5%. CONCLUSIONS:
Our analysis indicated that, under the new policy, the pro-
posed program reduced QALY loss, and reduced diabetic
retinopathy disease costs.
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OBJECTIVES: To evaluate the potential of clinical, de-
mographic and utilization factors in predicting treatment
costs for diabetic foot ulcers. METHODS: Retrospective
analysis of administrative outpatient pharmacy and med-
ical claims from 1/96–12/98 was conducted using Proto-
care Science’s Managed Care Database. Diabetic patients
were identified using diagnoses and medication claims.
Diagnosis of chronic skin ulcer of lower limbs defined
foot ulcer. Descriptive analysis of demographic, clinical,
and prior medical resource use information was per-
formed, followed by multivariate regression to estimate
the potential of these variables in explaining foot ulcer
treatment charges. RESULTS: The prevalence of diag-
nosed foot ulcers was 1.4% (2881 of the 212,563 identi-
fied diabetics). Patients with foot ulcers were older (mean
age 64.9 years vs. 60.7 years) and more likely to be male
(59.6% vs. 50%) than the non-foot ulcer diabetic popu-
lation. Diabetes-related complications and comorbidities
were common including skin infections, peripheral vascu-
lar disorders, and neurologic problems. During three
months following onset of foot ulcer, related care repre-
sented 40% of the $2596 average monthly charges per
patient. Using regression, demographic, clinical and prior
resource utilization information explained one-fifth of
the ulcer-related charges (R-square  0.22). Ulcer sever-
ity at onset, previous cellulitis or skin abscess, and pen-
toxifylline use were the strongest contributors. CON-
CLUSIONS: Although claims data cannot fully explain
variations in foot ulcer treatment costs, clinical factors,
such as markers for ulcer severity and active treatment of
peripheral vascular disease are predictors of treatment
costs. The correlation between previous skin problems
and treatment costs was negative, suggesting that height-
ened awareness through past experience may result in
lower treatment costs.
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OBJECTIVE: To compare direct medical costs of the
treatment of type-2 diabetic patients with hypertension,
hyperlipidemia, and no comorbidity. METHODS: The
study used an integrated medical and pharmacy claims
database from the Hawaii Medical Service Association.
Patients with at least one paid medical claim in the calen-
dar year 1995 for type-2 diabetes mellitus were selected.
Subsequently, these patients were segregated into three
mutually exclusive categories: patients with hypertension
as the sole comorbidity (Nhtn), patients with hyperlipi-
demia only (Nhlpd), and patients with no recorded comor-
bidity (Nnoco) in 1995. Average and median total medical
treatment costs as well as medical costs for the treatment
of diabetes and commonly associated comorbidities were
estimated for each population. RESULTS: Table 1 shows
sample size, age and gender distributions of three popula-
tions. Table 2 shows the total medical and diabetes and
associated comorbidity related medical costs of treat-
ment.
Table 1. Demography
Populations Sample size
Age
% femaleAverage Median
Nhtn 808 52 53 51.1
Nhlpd 657 50 51 47.6
Nnoco 623 45 47 52.3
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CONCLUSION: Average medical costs of treatment
were the highest for patients with no recorded comorbid-
ity in 1995. In contrast, the median cost estimates were
the lowest for these patients. Results indicated that distri-
butions of medical costs were positively skewed; the ob-
servation was most prominent in the population with no
recorded comorbidities associated with type-2 diabetes
mellitus. This finding may result from several factors in-
cluding coding, severity, and/or compliance.
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Diabetes is a chronic illness with type 2 diabetes repre-
senting 80% of all diagnosed diabetes. In recent years, a
number of instruments have been developed to measure
the HRQOL of patients with type 2 diabetes. Good psy-
chometric properties of these instruments are important
for their use in studies evaluating the effect of interven-
tions to increase metabolic control. OBJECTIVE: To re-
view the QOL literature with focus on HRQOL measure-
ments in type 2 diabetes. METHOD: We identified HRQOL
instruments for type 2 diabetes using MEDLINE (En-
glish), and reviewed the resulting publications for evi-
dence of reliability, validity, and responsiveness. RE-
SULTS: Several English-language generic and disease-
specific measures were identified. These instruments have
been used both in mixed diabetes populations and in
solely type 2 patients, including insulin users. The instru-
ments in the studies reviewed have acceptable reliability
and validity in tested populations. Few of these HRQOL
measures have been tested for sensitivity to changes in
metabolic control through pharmacological or non-phar-
macological interventions. One recently published drug
study provided support for the responsiveness of scales in
an unpublished HRQOL instrument. CONCLUSIONS:
Generic instruments such as the MOS SF-36 and EQ5D
may or may not be sensitive to change in HRQOL related
to diabetes and its treatment. Disease-specific instru-
ments have shown more sensitivity, but may fail to cap-
ture all relevant domains and do not apply to the specific
diabetes population under investigation. The responsive-
ness of instruments has not been addressed adequately in
the studies. More studies are needed to further assess reli-
Table 2. Medical costs ($)
Populations
Total
Diabetes and 
associated 
comorbidities
Average Median Average Median
Nhtn 1,964 471 427 184
Nhlpd 1,197 571 374 225
Nnoco 2,735 456 594 166
ability, validity and most importantly, responsiveness of
the existing instruments.
PDB9
COST OF CONCOMITANT ILLNESSES AMONG 
PATIENTS WITH HYPERTENSION
AND DIABETES
Farquhar IV1, Jackson JD1, Weir E2
1Bristol-Myers Squibb Company, Princeton, NJ, USA; 
2Analytical Computing, Baltimore, MD, USA
OBJECTIVE: To develop a method to test the hypothesis
that DM and HT are the most frequent concomitant ill-
nesses among such disease groups as cardiovascular
(CVD), joint disorders, renal failure, liver and kidney dis-
eases and to calculate the annual medical care costs of
HT and DM compared with estimated average care costs
in the disease groups. METHODS: Diagnosis-specific es-
timates for health care utilization and associated medical
expenses were constructed by employing a linear model
with exogenous population weights and normalizing co-
efficients using the National Medical Expenditure Survey
data. Statistical analyses for demographic parameters and
design effects on mean cost were obtained using linear re-
gression models. RESULTS: Among diabetics the most
prevalent conditions were HT (40%), CVD (26%), joint
disorders (23%), and fatigue (21%). DM and any of the
15 comorbidities incurred annual average costs ranging
from $2000 to $48,100, 1.5 to 3.5-fold higher than the
estimated disease-specific average costs. Among patients
with HT the most prevalent conditions were joint disor-
ders (23%), CVD (22%), fatigue (20%), and DM (18%).
HT and any of the 15 comorbidities incurred annual av-
erage medical costs 1.3–2.5-fold higher than the esti-
mated disease-specific average medical costs. Patients
with DM and HT constitute over 60% of all patients
treated annually for CVD, 52% for renal failure, 55%
for joint disorders and 45% with liver diseases. Federal
programs compensate 38% of medical care costs in HT
and 56% in DM. Out-of-pocket expenses pay 37% of
costs in HT and 20% in DM. CONCLUSION: Our find-
ings suggest that HT and DM are responsible for more
than 60% of health care costs in some of the 15 re-
searched disease categories. Treating of DM and HT to
goal will help to contain medical care costs for health
care providers and payers irrespective of any other co-
morbidity, and contribute to cost-effective disease man-
agement, and quality of care.
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